{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:06:40Z","timestamp":1789596400746,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014471","name":"Mundipharma Research Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program. Rezafungin was well tolerated and administered via once-weekly outpatient intravenous infusion for up to 39 weeks during the program, enabling hospital discharge and replacing daily antifungal infusions.<\/jats:p>","DOI":"10.1093\/ofid\/ofaf034","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T11:20:51Z","timestamp":1742383251000},"source":"Crossref","is-referenced-by-count":17,"title":["Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6541-9435","authenticated-orcid":false,"given":"Filippo","family":"Trapani","sequence":"first","affiliation":[{"name":"Infectious Disease Unit, Department of Oncology and Hematology, Guglielmo da Saliceto Hospital , Piacenza ,","place":["Italy"]},{"name":"Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3989-2520","authenticated-orcid":false,"given":"Giulio","family":"Viceconte","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Morena","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, \u201cA. Manzoni\u201d Hospital, ASST Lecco ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3884-4933","authenticated-orcid":false,"given":"Giusy","family":"Tiseo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana, University of Pisa , Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0399-2220","authenticated-orcid":false,"given":"Giovanni","family":"Mori","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Azienda Provinciale per i Servizi Sanitari (APSS) , Trento ,","place":["Italy"]},{"name":"Universita\u0300 Vita-Salute San Raffaele , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"K\u00f6lking","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Tropical Medicine, Centre for Infectious Diseases, Heidelberg Hospital , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Khatamzas","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Tropical Medicine, Centre for Infectious Diseases, Heidelberg Hospital , Heidelberg ,","place":["Germany"]},{"name":"German Centre for Infection Research (DZIF), Partner site Heidelberg University Hospital , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"2025031911201980800_ofaf034-B1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11046-024-00871-0","article-title":"Insights from three pan-European multicentre studies on invasive Candida infections and outlook to ECMM Candida IV","volume":"189","author":"Wolfgruber","year":"2024","journal-title":"Mycopathologia"},{"key":"2025031911201980800_ofaf034-B2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases\u2014estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J Fungi"},{"key":"2025031911201980800_ofaf034-B3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","article-title":"Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis","volume":"25","author":"Koehler","year":"2019","journal-title":"Clin Microbiol Infectn"},{"key":"2025031911201980800_ofaf034-B4","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/cid\/civ791","article-title":"Echinocandin resistance in Candida","volume":"61","author":"Perlin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025031911201980800_ofaf034-B5","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cmi.2019.03.028","article-title":"Resistance of Candida to azoles and echinocandins worldwide","volume":"25","author":"Pristov","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2025031911201980800_ofaf034-B6","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofz251","article-title":"Impact of initial antifungal therapy on the outcome of patients with candidemia and septic shock admitted to medical wards: a propensity score-adjusted analysis","volume":"6","author":"Falcone","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025031911201980800_ofaf034-B7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2025031911201980800_ofaf034-B8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025031911201980800_ofaf034-B9","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1080\/14787210.2023.2240956","article-title":"Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin","volume":"21","author":"Oliva","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025031911201980800_ofaf034-B10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/14656566.2024.2331775","article-title":"An evaluation of rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis","volume":"25","author":"Sharma","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"2025031911201980800_ofaf034-B11","doi-asserted-by":"crossref","first-page":"e01627-16","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031911201980800_ofaf034-B12","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031911201980800_ofaf034-B13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/jof6040262","article-title":"Rezafungin\u2014mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins","volume":"6","author":"Garcia-Effron","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2025031911201980800_ofaf034-B14","doi-asserted-by":"crossref","first-page":"e0133923","DOI":"10.1128\/spectrum.01339-23","article-title":"Absence of clinically meaningful drug-drug interactions with rezafungin: outcome of investigations","volume":"11","author":"Flanagan","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2025031911201980800_ofaf034-B15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ja.2016.89","article-title":"CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility","volume":"70","author":"Krishnan","year":"2017","journal-title":"J Antibiot (Tokyo)"},{"key":"2025031911201980800_ofaf034-B16","author":"Mundipharma GmBH"},{"key":"2025031911201980800_ofaf034-B17","author":"Napp Pharmaceutical Limited"},{"key":"2025031911201980800_ofaf034-B18","author":"Melinta Therapeutics LLC"},{"key":"2025031911201980800_ofaf034-B19","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025031911201980800_ofaf034-B20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"2025031911201980800_ofaf034-B21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1473-3099(23)00551-0","article-title":"Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials","volume":"24","author":"Thompson","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025031911201980800_ofaf034-B22","doi-asserted-by":"crossref","first-page":"e0075024","DOI":"10.1128\/aac.00750-24","article-title":"Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy)","volume":"68","author":"Ponta","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031911201980800_ofaf034-B23","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/microorganisms12050903","article-title":"Salvage therapy with rezafungin for Candida parapsilosis spondylodiscitis: a case report from Expanded Access Program","volume":"12","author":"Viceconte","year":"2024","journal-title":"Microorganisms"},{"key":"2025031911201980800_ofaf034-B24","doi-asserted-by":"crossref","first-page":"dlae042","DOI":"10.1093\/jacamr\/dlae042","article-title":"Treatment of Candida glabrata native valve endocarditis with rezafungin: a case report","volume":"6","author":"Mori","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2025031911201980800_ofaf034-B25","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/jac\/dkz390","article-title":"In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae","volume":"74","author":"T\u00f3th","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025031911201980800_ofaf034-B26","doi-asserted-by":"crossref","first-page":"dlad079","DOI":"10.1093\/jacamr\/dlad079","article-title":"Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis","volume":"5","author":"Jeck","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"2025031911201980800_ofaf034-B27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MD.0b013e3181a693f8","article-title":"Candida infective endocarditis: report of 15 cases from a prospective multicenter study","volume":"88","author":"Falcone","year":"2009","journal-title":"Medicine"},{"key":"2025031911201980800_ofaf034-B28","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/14787210.2017.1372749","article-title":"Candida endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian study of endocarditis","volume":"15","author":"Giuliano","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025031911201980800_ofaf034-B29","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/14787210.2021.1926986","article-title":"Diagnostic stewardship based on patient profiles: differential approaches in acute versus chronic infectious syndromes","volume":"19","author":"Tiseo","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025031911201980800_ofaf034-B30","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/jac\/dkad139","article-title":"Invasive candidiasis: current clinical challenges and unmet needs in adult populations","volume":"78","author":"Soriano","year":"2023","journal-title":"J Antimicrob Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/3\/ofaf034\/62452685\/ofaf034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/3\/ofaf034\/62452685\/ofaf034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T11:21:01Z","timestamp":1742383261000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf034\/8086845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf034","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,2,28]]},"article-number":"ofaf034"}}